Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
Lethal slipped into the ring and hit a Lethal Injection on Bandido and then the Swirl stomped him. All three beat on Bandido ...
A treatment that blocks an age-related protein restored cartilage in aging and injured joints by reprogramming existing cells ...
Your health should be your top priority at all times. It is the foundation for everything else that you do in life. You know ...
Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback